Previous close | 42.52 |
Open | 42.40 |
Bid | 0.00 x 1000 |
Ask | 0.00 x 1800 |
Day's range | 42.40 - 42.78 |
52-week range | 28.10 - 45.76 |
Volume | |
Avg. volume | 37,320 |
Market cap | 1.608B |
Beta (5Y monthly) | 0.60 |
PE ratio (TTM) | 29.92 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | 10 Dec 2018 |
1y target est | N/A |
Amicus' (FOLD) lead drug, Galafold, is witnessing solid uptake since its launch. The drug holds blockbuster potential. However, overdependence on Galafold for revenues remains a concern.
Iovance (IOVA) is likely to pause enrollment in the phase II IOV-LUN-202 study evaluating its tumor infiltrating lymphocyte therapy, LN-145, for treating non-small cell lung cancer. Stock declines.
The FDA clears Senti Bio's (SNTI) investigational new drug application for SENTI-202 for the treatment of relapsed/refractory hematologic malignancies, including acute myeloid leukemia. Stock rises.